{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-008030","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.275069+00:00","generated_at":"2026-06-27T02:53:31.478514+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO","bullets":["Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.","Cash $439.9M at Dec 31; FY2022 R&D guidance $130-140M, total opex $160-170M.","Kate Madigan appointed CMO effective March 1, succeeding Michael Meyers who retires.","Pivotal trials for SNDX-5613 and axatilimab enrollment on track; topline data expected 1H2023, potential NDA/BLA filing 2023.","Three new trials of SNDX-5613 expected to initiate 1H2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-008030","json":"https://secwatch.observer/filing/0001564590-22-008030.json","markdown":"https://secwatch.observer/filing/0001564590-22-008030.md","text":"https://secwatch.observer/filing/0001564590-22-008030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/sndx-8k_20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:53:31.478514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6232a0a19b","claim":"Kate Madigan was appointed as Chief Medical Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"Kate Madigan, M.D. will join the Company as Chief Medical Officer, effective March 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"b918bfe73b","claim":"Michael L. Meyers departed as Chief Medical Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of the Company, notified the Company of his intention to retire and resign from his position as Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired and resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}